Badarch, Bat-Ireedui

Товч нэр

Бүтэн нэр

Badarch Bat-Ireedui

Латин нэр

Badarch Bat-Ireedui

Албан тушаал

Судлаач

Харьяалал

Анагаахын Шинжлэх Ухааны Үндэсний Их Сургууль

Now showing 1 - 10 of 15

Some of the metrics are blocked by your
consent settings
335.6: The role of international collaboration in developing transplant programs: A success story from TTS-ILTS paired transplant centers program from the Paired program.
(Wolters Kluwer, 2026-08-24)
Sergelen Orgoi
;
Batsaikhan Bat‐Erdene
;
Sarnai Erdene
;
Batsaikhan Batsuuri
;
Ganzorig Batjargal
Some of the metrics are blocked by your
consent settings
Post Liver Transplantation Renal Impairment: Experience With the First 100 Cases in a Single Center in Mongolia
(2022)
Batsuuri, Batsaikhan
;
Lopez-Verdugo, Fidel
;
Badarch, Bat-Ireedui
;
Martinez, Angel Flores Huidobro
;
Erdene, Sarnai
Some of the metrics are blocked by your
consent settings
Renal Dysfunction After Liver Transplantation: a Single Center Study
(Mongolian National University of Medical Sciences, 2021-12-31)
Batsaikhan Batsuuri
;
Fidel López‐Verdugo
;
Bat-Ireedui Badarch
;
Suvd Nergui
;
Ariunaa Togtokh
Objectives: Mongolia is known as one of the countries with a high prevalence of viral hepatitis infection and its related liver cirrhosis and HCC. Therefor, liver transplantation (LT) surgery increases from year to year in Mongolia. Our goal was to evaluate post-transplant renal dysfunction (PTRD) and to investigate the predicting factors for renal dysfunction after LT. Methods: The impact of graft ischemic time, peri- and postoperative blood product transfusion, perioperative hemodynamics, time to extubating, intensive care length of stay, incidence of chronic renal failure, and mortality and morbidity were examined alone and then as a combined outcome. Results: Early renal dysfunction was identified by measuring serum creatinine and glomerular filtration rate. In our investigation which was a study group of patients following liver transplantation (LT), the following renal dysfunctions were found: 39% of recipients in the study had renal dysfunction, while the rest had no renal dysfunction. The average creatinine level of the recipients who had a renal dysfunction after LT, was 0.825 ± 0.24 mg/dl and the glomerular filtration rate was 111 ± 36.3 ml/min, and statistically significant. Conclusion: Preoperative kidney function plays a crucial role for postoperative renal dysfunction.
Some of the metrics are blocked by your
consent settings
Hepatic arterial reconstruction using saphenous vein graft interposition for living donor liver transplantation
(2023-06-08)
Batsaikhan Bat‐Erdene
;
Bat-Ireedui Badarch
;
Sergelen Orgoi
;
Erdene Sandag
;
Batsaikhan Batsuuri
Batsaikhan BAT-ERDENE*, Bat-Ireedui BADARCH, Sergelen ORGOI, Erdene SANDAG, Batsaikhan BATSUURI, Urnult GANBOLD, Otgonbayar SETEVDORJ. Ann Hepatobiliary Pancreat Surg 2023;27:S313. https://doi.org/10.14701/ahbps.2023S1.EP-46
Some of the metrics are blocked by your
consent settings
Inferior vena cava stenosis-induced sinusoidal obstructive syndrome after living donor liver transplantation
(The Korean Association of Hepato-Biliary-Pancreatic Surgery, 2016-08)
Bat-Erdene, Batsaikhan
;
Orgoi, Sergelen
;
Sandag, Erdene
;
Namkhai, Ulzii-Orshikh
;
Badarch, Bat-Ireedui
The sinusoidal obstructive syndrome (SOS) is a complication that usually follows hematopoietic stem cell transplantation. It is also known as veno-occlusive disease, which is a rare complication of living donor liver transplantation (LDLT). Herein, we reported a 34 year-old female patient presenting SOS after LDLT. Its underlying cause was presumed to be associated with liver abscess and subsequent inferior vena cava stenosis. SOS led to graft failure, thus requiring retransplantation with a deceased donor liver graft. The underlying causes of SOS are complex pathologic entity with multifactorial etiology. It is likely that its multifactorial etiology includes a decrease of hepatic venous outflow that is caused by graft liver infection and inferior vena cava stenosis.
Some of the metrics are blocked by your
consent settings
Nonsurgical treatment of abdominal compartment syndrome in a patient following living donor liver transplantation: a case report
(The Korean Society for Transplantation, 2022-11-17)
Erdene, Sarnai
;
Setevdorj, Otgonbayar
;
Badarch, Bat-Ireedui
;
Batsuuri, Batsaikhan
;
Batjargal, Ganzorig
Some of the metrics are blocked by your
consent settings
Massive gastrointestinal bleeding following living donor liver transplantation: a case report
(The Korean Society for Transplantation, 2022-11-17)
Ganbaatar, Bayarbileg
;
Badarch, Bat-Ireedui
;
Batsuuri, Batsaikhan
;
Orgoi, Sergelen
;
Sainbyan, Tamir
Some of the metrics are blocked by your
consent settings
BUILDING A SELF-SUFFICIENT LIVER TRANSPLANT PROGRAM IN MONGOLIA
(Ovid Technologies (Wolters Kluwer Health), 2020-09)
Banzragch, Ganzorig
;
Batsuuri, Batsaikhan
;
Badarch, Bat-Ireedui
;
Sainbuyan, Tamir
;
Erdene, Sarnai
Some of the metrics are blocked by your
consent settings
Impact factors leading to renal impairment after liver transplant surgery: a single center study
(2022-11-14)
Batsaikhan Batsuuri
;
Shiirevnyamba Avirmed
;
Bat-Ireedui Badarch
;
Fidel López‐Verdugo
;
Ariunaa Togtokh
Batsaikhan Batsuuri, Shiirevnyam Avirmed, Bat-Ireedui Badarch, Fidel Lopez-Verdugo, Ariunaa Togtokh, Shiirevnyam Avirmed, Sergelen Orgoi. Korean J Transplant 2022;36:195. https://doi.org/10.4285/ATW2022.F-3297
Some of the metrics are blocked by your
consent settings
P.389: No difference in recurrent hepatocellular carcinoma rates in liver transplanted patients receiving mTOR inhibitors compared to non-mTOR group.
(Wolters Kluwer, 2024-09-01)
Anar Ganbold
;
Margad-Erdene Erdenechuluun
;
Bayarmaa Ochirkhuree
;
Urnultsaikhan Ganbold
;
Ulzii-Orshikh Namkhai
Introduction: A liver transplantation (LT) is a first line therapeutic choice for patients with hepatocellular carcinoma (HCC). Mammalian Target of Rapamycin (mTOR) inhibitors act as immunosuppressant and indicated against HCC recurrence in LT patients. The efficacy of mTOR inhibitors in preventing HCC recurrence remains contentious. Methods: We retrospectively enrolled 45 patients (average age 50, M/F:29/16) who had a history of HCC at the time of LT operation at a single center (2011-2023) and divided into a mTOR and non-mTOR groups. Initial Alfa-fetoprotein (AFP), Protein induced by vitamin K absence-II (PIVKA-II) levels, contrast-enhanced abdominal computer-assisted tomography (CT) scans were compared to most recent results, explant histology was also assessed for HCC extent. Decision to transplant was made based on Milan criteria. Student t-test was used to determine statistical significance (p<0.05). Results: In the mTOR group (n=23, average age 52.7) there were 2 confirmed HCC recurrences with elevated markers and positive CT scans. In the non-mTOR group (n=22, average age 47.4) there was 1 confirmed case of HCC. A recurrence rate of 6.67% was recorded overall, 8.7% and 4.55% for mTOR and non-mTOR (p=0.28), respectively. All three recurrences were detected within 24 months of the operation. For recurrent HCCs, the average levels of PIVKA-II and AFP were 27010mAU/ml and 2842.7ng/ml, respectively. There was no difference in number and mode of pre-LT bridging therapies (TACE or RFA) with regards to recurrence. There were two cases of elevated PIVKA-II without a radiologic confirmation. Conclusion: Adherence to the Milan criteria and application of pre-LT bridging therapies will keep the recurrence rate below 10%. Any possible recurrence will be diagnosed within 24 months of LT. Administration of mTOR inhibitors can be stopped after 2 years as part of the physician-guided minimization of immune suppression regimen.

Badarch, Bat-Ireedui

Filters

Settings

Sort By

Results per page